JJJames Jackson

James Jackson

*This is an algorithmically generated author record based on publicly available information.

James Jackson has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differences in Patient-Physician Satisfaction for Migraine Treatment Medications in Patients with and without Medication-Overuse Headache: A Cross-Sectional Real-World Survey

    by Ryotaro Ishii, Takahiro Kitano, Masahiro Iijima, Mitsuhiro Nagano, Reiko Yoshikawa, James Jackson, Sophie Barlow, Emily Green, William Whitton, Lucy Hargreaves, et al.

    Introduction Medication overuse headache (MOH) is incurred by the excessive use of acute medications, including over-the-counter (OTC) treatments. This study aimed to characterize the burden, management, and treatment satisfaction of patients with migraine with or without MOH in Japan. Methods Data were derived from the Adelphi Migraine Disease Specific Programme (DSP)™, a cross-sectional survey conducted in Japan from August 2023 to February 2024. Physicians provided data for consecutive patients, including demographics, clinical characteristics, current treatment, OTC treatment usage, and treatment satisfaction. Patients voluntarily reported their symptom burden, migraine pain severity, and treatment satisfaction. Alignment between physician and patient regarding treatment satisfaction was assessed using Cohen’s weighted kappa statistics and multivariable regression models. Results Overall, 122 physicians provided data for 820 patients with migraine, 7.0% (n = 57) of whom had a diagnosis of MOH; 41.5% (n = 340) of patients self-reported data, with 3.2% (n = 11) having a diagnosis of MOH. Patients with MOH were more likely to experience chronic migraine (79%, n = 45), greater migraine frequency, and more severe migraine than those without MOH. Ninety percent of both groups received acute treatment. Patients with MOH were significantly more likely to receive preventive treatment than those without MOH (86% vs 56.6%, p < 0.001). OTC medication use was reported at 3.3% by physicians and 11.2% by patients. The alignment between physician and patient treatment satisfaction was low for acute treatment. The exploratory model analysis indicated that OTC use may have contributed to this misalignment. Conclusion Our study revealed that the alignment regarding treatment satisfaction with acute medications is low. OTC treatment usage may have inflated physician satisfaction with prescribed acute medications and caused a discrepancy regarding satisfaction of patients with MOH. To improve patient outcomes, it is essential to align drug effectiveness ratings between physicians and patients by enhancing communication and mutual understanding.

  • Open Access

    Underdiagnosis and impact of menstrual migraine in real‐world clinical practice: A real‐world survey

    by Gisela Terwindt, Jessica Ailani, Jessica Cirillo, Lucy Abraham, Aaron Jenkins, Phillip Saccone, Karin Hygge Blakeman, Feng Dai, James Jackson, Sophie Barlow, et al.

    Objective: This cross‐sectional study aimed to evaluate the frequency of menstrual migraine (MM) reporting in clinical practice and to compare the clinical burden, treatment patterns, and patient satisfaction between those with and without MM.Background: People with MM experience more severe, disabling, and prolonged attacks than people with non‐MM. Research indicates that approximately two thirds of females with migraine may experience MM; however, the prevalence of MM is often underreported and there is a lack of awareness regarding the condition.Methods: This study analyzed secondary data from the Adelphi Real World Migraine Disease Specific Programme™, a cross‐sectional survey with retrospective data collection conducted across France, Germany, Italy, Spain, the United Kingdom, and the United States from May 2022 to February 2024. Physicians completed an attitudinal survey, and provided data for consecutively consulting patients with migraine, containing questions on demographics, clinical characteristics, treatment history (including reasons for treatment choice, treatment satisfaction, and adherence), and symptomatic burden. Patients voluntarily completed a questionnaire on their current symptom burden, migraine pain severity, treatment satisfaction, and other patient‐reported outcomes. Outcomes between patients with and without a physician‐confirmed diagnosis of MM were compared using statistical and comparative tests. Patients were eligible for inclusion if they were female, aged 18–55 years, and had menstrual periods.Results: Overall, 627 physicians reported data on 3215 patients who met the inclusion criteria, with 1037 (32.3%) having a physician‐confirmed diagnosis of MM. The patient questionnaire was completed by 931 patients, of whom 340 (36.5%) had a physician‐confirmed diagnosis of MM. While physicians estimated on average that 38.5% of their patients experienced MM, 32.3% of patients had a physician‐confirmed diagnosis of MM, as reported from the individual patient record forms. Additionally, 14.0% of patients without a physician‐confirmed diagnosis of MM self‐reported menstruation as a trigger for their migraine. Clinically, there were few differences observed between patient groups, except for higher migraine attack severity in patients with MM (p < 0.001). Patients with and without MM were prescribed a similar number of acute treatments (mean [standard deviation, SD]: both 1.1 [0.7]), but patients with physician‐confirmed MM were prescribed fewer preventive treatments (mean [SD]: 0.5 [0.6] vs. 0.6 [0.6], p < 0.001). Lower physician‐reported satisfaction with acute (21.6% vs. 29.4%, p = 0.024) and preventative treatment (22.0% vs. 34.8%, p = 0.010) was observed in patients with MM compared to those without MM. Patients with MM also reported less satisfaction with their acute treatment than those without MM (19.4% vs. 27.8%, p = 0.013).Conclusions: This study highlights differences between patients with and without MM. Patients with MM experienced more severe attacks and reported lower treatment satisfaction, according to both patients and their physicians, compared to those without MM. Further real‐world insights on patient experience, including migraine attack severity, are necessary to alleviate the burden of MM.


  • Open Access

    Replicating the real-world evidence methods available in human health to assess burden and outcomes for dogs with chronic kidney disease, their owners, and the veterinary healthcare system in the United States of America

    by Andrea Wright, Dean Taylor, Mollie Lowe, Sophie Barlow, James Jackson

    Introduction: Chronic kidney disease (CKD) in canines is a progressive condition characterized by a gradual decline in kidney function. There are significant gaps in understanding how CKD is managed in canines and the full extent of its impact. This study aimed to characterize disease management of CKD and its impact on dogs, their owners and the veterinary healthcare system in the United States of America (United States).Methods: Data were drawn from the Adelphi Real World Canine CKD Disease Specific Programme™, a cross-sectional survey of veterinarians, pet owners and their dogs with CKD in the United States from December 2022 to January 2024. Veterinarians reported demographic, diagnostic, treatment, and healthcare utilization data, for dogs with CKD. Owners voluntarily completed questionnaires, providing data about their dog, as well as quality of life and work-related burden using the Dog Owners Quality of Life, and the Work Productivity and Activity Impairment questionnaires. Analyses were descriptive and Cohen’s Kappa was used to measure agreement between owners and veterinarians.Results: A total of 117 veterinarians provided data for 308 dogs, of which 68 owners also reported information. Discrepancies in recognizing symptoms of CKD in dogs, particularly excessive water consumption and urination, were identified between veterinary professionals and owners. Interventions for managing CKD in dogs focused on controlling symptoms and supporting kidney function through dietary modifications and medication. Owners of dogs with CKD reported minimal impact to overall work and activity impairment (10 and 14%, respectively). At diagnosis, 78.6% of dogs were International Renal Interest Society Stage I-II, and 21.5% were Stage III-IV. Regardless of CKD stage, owners strongly agreed that ownership provided them with emotional support and companionship. Regarding veterinary healthcare utilization, 95% of dogs were seen in general veterinary practices.Discussion: These findings emphasize the value of real-world evidence in enhancing our understanding of CKD in companion animals and informs future strategy for the real-world diagnosis and treatment of CKD. The results also provide insights to the potential burden experienced by owners of dogs with CKD.


  • Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany

    by Sarah Cotton, Jeffrey S. Andrews, Russell M. Nichols, James Jackson, Antje Tockhorn-Heidenreich, Gary Milligan, James M. Martinez

    Objective: To describe clinical characteristics and regional treatment patterns of episodic cluster headache (CH). Methods: A point-in-time survey of physicians and their patients with CH was conducted in the United States, United Kingdom and Germany in 2017. Results: Overall, 1012 patients with episodic CH were analyzed. Demographic and clinical findings were generally consistent across regions. Most patients were men (66.6%) and the mean age was 40.9 years. The greatest proportion of patients (38.3%) had <= 1 attack per day. The mean number of attacks per day (APD) was 2.4 and mean number of cluster periods per year was 2.6; the mean cluster period duration was 30.8 days. Most patients (69.3%) did not report a specific or predicable time when cluster periods occurred. Acute treatment was prescribed for 47.6% of patients, 10.3% of patients received preventive treatment, and 37.9% of patients received combined acute and preventive treatment; 4.2% of patients were not receiving treatment. Frequently prescribed acute treatments were sumatriptan, oxygen, and zolmitriptan; oxygen use varied considerably across countries and was prescribed least often in the United States. Frequently prescribed preventive treatments were verapamil, topiramate, and lithium. Lack of efficacy and tolerability were the most common reasons for discontinuing preventive treatment. Conclusions: We observed high use of acute treatments, but only half of patients used preventive treatments despite experiencing several cluster periods per year with multiple cluster APD. Further studies about the need for and benefits of preventive treatment for episodic CH are warranted. PLAIN LANGUAGE SUMMARY People with cluster headache (CH) experience headache attacks of excruciating stabbing pain, usually on one side of the head around the eye. These headache attacks typically last between 15 min and 3 h, and come in clusters (or bouts) occurring up to several times a day for a few weeks or months at a time. This greatly impacts a patient's quality of life. We surveyed doctors and their patients across the United States, the United Kingdom and Germany, looking at symptoms that occurred during CH attacks, how long the headache attacks lasted, how often the patient had them, and what medicines were being given. Our results showed that patients with CH suffered from clusters (bouts) of headache attacks several times a year. Nearly, a third of patients had a wrong diagnosis before being diagnosed with CH. Patients experienced stress, agitation, restlessness, difficulty relaxing and depression during a headache attack, especially those who had more CH attacks each day. Although many patients were taking medication, only half of patients were prescribed medicines to prevent their headache attack from starting. Side effects and the medicines not working were the most common reasons patients stopped taking medicine to prevent their headache attacks. The differences seen in medicines prescribed between countries suggest differences in guidance, or in doctors' awareness of current medication guidelines. Further studies about the need for and benefits of medicines to prevent CH attacks are needed.


  • Open Access

    Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction

    by Thomas J. Schnitzer, Rebecca L. Robinson, Lars Viktrup, Joseph C. Cappelleri, Andrew G. Bushmakin, Leslie Tive, Mia Berry, Chloe Walker, James Jackson

    Patients often take opioids to relieve osteoarthritis (OA) pain despite limited benefits and potential harms. This study aimed to compare cross-sectional perspectives of patients that were taking prescription opioid (N = 471) or nonopioid medications (N = 185) for OA in terms of satisfaction, expectations of effectiveness, and concerns. Patients prescribed opioids (>7 days) reported more prior treatments (2.47 vs. 1.74), greater mean pain intensity (5.47 vs. 4.11), and worse quality of life (EQ-5D-5L index value mean 0.45 vs. 0.71) than patients prescribed nonopioid medications (all p < 0.0001). Based on linear regression models adjusting for demographics and pain intensity, patients prescribed opioids were less satisfied with overall regimen (3.40 vs. 3.67, p = 0.0322), had less belief that medications were meeting effectiveness expectations (2.72 vs. 3.13, p < 0.0001), and had more concerns about treatments being “not very good” (3.66 vs. 3.22, p = 0.0026) and addiction (3.30 vs. 2.65, p < 0.0001) than patients prescribed nonopioid regimens. When the models were replicated for subgroups with ≥30 days’ medication regimen duration, the findings were consistent with the main analyses. Patients have concerns about the risk of opioid addiction, but those with greater disease burden and more prior treatments continue taking opioid regimens.


  • Open Access

    Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China

    by Lei Zhang, Diego Novick, Shiying Zhong, Jinnan Li, Chloe Walker, Lewis Harrison, James Jackson, Sophie Barlow, Sarah Cotton

    Introduction Migraine is a common disabling primary headache disorder characterized by attacks of severe pain, sometimes accompanied by symptoms including nausea and photo-/phono-phobia. Real-world data of patients with migraine who sufficiently (responders) and insufficiently (insufficient responders) respond to acute treatment (AT) are limited in China. This analysis explored whether responders to AT differ from insufficient responders in terms of clinical characteristics, treatment patterns, and patient-reported outcomes in China. Methods Data were drawn from the Adelphi Migraine Disease Specific Programme™, a point-in-time survey of internists/neurologists and their consulting patients with migraine, conducted in a real-world setting in China, January–June 2014. Responders and insufficient responders to prescribed AT were patients who typically achieved headache pain freedom within 2 h of AT in ≥ 4 and ≤ 3 of five migraine attacks, respectively. Responders were compared with insufficient responders; logistic regression was used to identify factors associated with insufficient response. Results Of 777 patients currently receiving AT, 44.0% were insufficient responders. Significantly fewer responders than insufficient responders had migraine with aura (13.1 vs. 23.8%; p = 0.0001). Responders reported a significantly lower mean Migraine Disability Assessment (MIDAS) total score (5.5 vs. 6.6; p = 0.0325). Responders reported a lower mean impairment while working (50.0 vs. 63.9%; p < 0.0001), overall work impairment (52.6 vs. 66.0%; p < 0.0001), and activity impairment (48.9 vs. 59.0%; p < 0.0001). Statistically significant factors associated with insufficient response to AT included diabetes, unilateral pain, vomiting, sensitivity to smell, visual aura/sight disturbance, and an increase in MIDAS total score. However, there were no statistically significant differences in ATs received by responders and insufficient responders at any regimen of therapy. Conclusions Many patients with migraine in China are insufficient responders to AT, experiencing worse symptoms that lead to overall poorer quality of life than responders. This unmet need suggests that new effective treatment options are required for migraine.


  • Open Access

    Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons

    by Thomas J. Schnitzer, Rebecca L. Robinson, Lars Viktrup, Joseph C. Cappelleri, Andrew G. Bushmakin, Leslie Tive, Mia Berry, Chloe Walker, James Jackson

    Opioids are often prescribed for osteoarthritis (OA) pain, despite recommendations to limit use due to minimal benefits and associated harms. This study aimed to assess physicians’ practice patterns and perceptions regarding opioids by specialty one year following the Centers for Disease Control and Prevention (CDC) published guidance on opioid prescribing. The 139/153 (90.8%) physicians who reported prescribing opioids in the previous year reported decreased prescribing for mild OA (51.3%, 26.5% and 33.3% of primary care physicians, rheumatologists, and orthopaedic surgeons, respectively), moderate OA (50.0%, 47.1% and 48.1%) and severe OA (43.6%, 41.2% and 44.4%). Prescribing changes were attributed to the CDC guidelines for 58.9% of primary care physicians, 59.1% of rheumatologists, and 73.3% of orthopaedic surgeons. Strong opioids were mostly reserved as third-line treatment. Although treatment effectiveness post-CDC guidelines was not assessed, perceptions of efficacy and quality of life with opioids significantly differed across specialties, whereas perceptions of safety, convenience/acceptability and costs did not. Physicians generally agreed on the barriers to opioid prescribing, with fear of addiction and drug abuse being the most important. Across specialties, physicians reported decreased opioid prescribing for OA, irrespective of OA severity, and in most cases attributed changes in prescribing to the CDC guideline.


  • Open Access

    Physician and patient perceptions of surgical procedures for osteoarthritis of the knee in the United States, Europe, and Japan: results of a real-world study

    by N Fukui, Pg Conaghan, K Togo, N Ebata, L Abraham, J Jackson, M Berry, Jc Cappelleri, H Pandit

    Background: Osteoarthritis (OA) is the most common form of arthritis, with the knee being the joint most frequently affected, and symptomatic knee OA affecting around one quarter of the general population. For patients who do not respond to non-pharmacologic or pharmacologic treatment, surgery is a recommended option. The objectives of this study were to compare the willingness of patients with knee OA to undergo surgery, together with reasons for delaying surgery, and factors affecting successful outcomes. Methods: A point-in-time survey was conducted in 729 primary care physicians, rheumatologists, orthopedic surgeons, and 2,316 patients with knee OA across three geographical regions: Japan, the United States (US), and Europe (EUR: France, Spain, Italy, Germany, and the United Kingdom), in order to garner their perceptions of knee surgery. Regression models were used to identify factors that might affect patients’ and physicians’ perceptions of surgery, including severity of OA (mild/moderate/severe), number of affected joints, surgery status, and willingness to undergo or delay surgery. Results: Baseline demographics were similar between US and EUR, although patients in Japan were more likely to be female, older, and only 7% in fulltime employment. We found that few patients with end-stage knee OA, across all regions, but particularly Japan, were willing to undergo surgery (Japan 17%, US 32%, EUR 38%), either through fear, or the lack of awareness of the risk/benefits. Moreover, surgeons are prepared to delay surgery in elderly or unwilling patients, due to their dissatisfaction with the outcome, and may defer surgery in younger patients due to the need for future revision. We also identified a disconnect between physicians, of whom over 80% consider improved functioning to be the most important outcome of surgery, and patients, who seek pain relief (Japan 60%, US 35%, EUR 14%). Since physicians across all regions considered pain reduction to be an indication of surgery success (Japan 27%, US 47%, EUR 43%), this may indicate a need for improved communication to patients on the potential benefits of surgery. Conclusion: Managing the expectations of patients undergoing surgery remains an important goal in the treatment of knee OA and may help guide physician choice.


  • Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data

    by Pg Conaghan, L Abraham, L Viktrup, Jc Cappelleri, C Beck, Ag Bushmakin, M Berry, J Jackson

    To understand treatment patterns and healthcare resource utilization (HCRU) related to osteoarthritis (OA) disease severity in patients in five European countries.Data were drawn from the Adelphi O...


  • Open Access

    Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis

    by Louis P. Garrison, Patricia Schepman, Andrew G. Bushmakin, Rebecca L. Robinson, Leslie Tive, Jerry Hall, Mendwas Dzingina, James Jackson, Mia Berry, Joseph C. Cappelleri, et al.

    Purpose: To evaluate the relationship between self-reported concerns about becoming addicted to a medication and health-related quality of life (HRQoL) in patients with osteoarthritis (OA). Methods: This real-world study used patient-level cross-sectional survey data collected from the US Adelphi Disease Specific Programme (DSP). The DSP for OA selected 153 physicians who collected de-identified data on their next nine adult patients with OA. Each patient completed a disease-relevant survey, which included the Likert-scale question, “I am concerned about becoming addicted to my medicine,” (CAA) with responses ranging from “completely disagree” [1] to “completely agree” [5]. HRQoL was measured by the EQ-5D-5L index value and the EQ Visual Analogue Scale (VAS). A set of ordinary least squares regressions using HRQoL measures as outcomes and CAA as a continuous predictor were estimated. Standardized effect size (ES) was used to gauge the magnitude of effects. Results: A total of 866 patients with OA completed the survey (female, 61.2%; White, 77.7%; mean age, 64.2 years). Of the 775 patients who completed the CAA question, almost one-third responded that they “agree” (18%) or “completely agree” (11%), while 27% responded “completely disagree” and 20% “disagree.” Regression analyses found that patients who have concerns about medication addiction have significantly different EQ-5D-5L index values and EQ VAS scores compared with patients who do not have this concern (p < 0.0001). Conclusion: Our findings suggest that concern about medication addiction in patients with OA may have an impact on patient HRQoL, with more concerned patients reporting poorer HRQoL outcomes.